Insight

Amalya Sargsyan: Will surgery be reconsidered for dMMR tumors achieving CR?

Amalya Sargsyan/X

Apr 29, 2025, 17:03

Amalya Sargsyan: Will surgery be reconsidered for dMMR tumors achieving CR?

Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“Will surgery be reconsidered for dMMR tumors achieving CR? ctDNA=?

Presented at AACR2025 by Andrea Cercek and Team MSK (published in NEJM)

Neoadjuvant immunotherapy with Dostarlimab in early-stage dMMR cancers shows very promising results

100% cCR in 49 rectal cancer patients
65% cCR across 10 other cancers (n=54)
Safe approach – all non-CR or recurrence cases were salvaged

Among 84 patients with CR, 82 skipped surgery and remained recurrence-free.

2-year recurrence-free survival is 92%

All authors: Andrea Cercek, M.D., Michael B. Foote, M.D., Benoit Rousseau, M.D., Ph.D., J. Joshua Smith, M.D., Ph.D., Jinru Shia, M.D., Jenna Sinopoli, N.P., Jill Weiss, B.S., Melissa Lumish, M.D. Lindsay Temple, B.A., Miteshkumar Patel, M.S., Callahan Wilde, B.A., Leonard B. Saltz, M.D., Guillem Argiles, M.D., Zsofia Stadler, M.D., Oliver Artz, Ph.D., Steven Maron, M.D., Geoffrey Ku, M.D., Ping Gu, M.D., Yelena Y. Janjigian, M.D., Daniela Molena, M.D., Gopa Iyer, M.D., Jonathan Coleman, M.D., Wassim Abida, M.D., Seth Cohen, M.D., Kevin Soares, M.D., Mark Schattner, M.D., Vivian E. Strong, M.D., Rona Yaeger, M.D., Philip Paty, M.D., Marina Shcherba, M.D., Ryan Sugarman, M.D., Paul B. Romesser, M.D., Alice Zervoudakis, M.D., Avni Desai, M.D., Neil H. Segal, M.D., Ph.D., Imane El Dika, M.D., Maria Widmar, M.D., Iris Wei, M.D., Emmanouil Pappou, M.D., Ph.D., Gerard Fumo, M.D., Santiago Aparo, M.D., Mithat Gonen, M.D., Marc Gollub, M.D., Vetri S. Jayaprakasham, M.B., B.S., Tae-Hyung Kim, M.D., Julio Garcia Aguilar, M.D., Ph.D., Martin Weiser, M.D., and Luis A. Diaz, Jr., M.D.

Read the paper “Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab” in OncoDaily.

Amalya Sargsyan: Will surgery be reconsidered for dMMR tumors achieving CR?